BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18438800)

  • 1. The discovery of antiviral agents: ten different compounds, ten different stories.
    De Clercq E
    Med Res Rev; 2008 Nov; 28(6):929-53. PubMed ID: 18438800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Advances in the study of nucleoside antiviral drugs].
    Liu K; Xie L
    Yao Xue Xue Bao; 2006 Aug; 41(8):689-93. PubMed ID: 17039770
    [No Abstract]   [Full Text] [Related]  

  • 3. The Holý Trinity: the acyclic nucleoside phosphonates.
    De Clercq E
    Adv Pharmacol; 2013; 67():293-316. PubMed ID: 23886004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge.
    De Clercq E
    Biochem Pharmacol; 2007 Apr; 73(7):911-22. PubMed ID: 17045247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of kinase bypass strategies to nucleoside antivirals.
    Ray AS; Hostetler KY
    Antiviral Res; 2011 Nov; 92(2):277-91. PubMed ID: 21878354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and antiviral activity evaluation of acyclic 2'-azanucleosides bearing a phosphonomethoxy function in the side chain.
    Koszytkowska-Stawińska M; De Clercq E; Balzarini J
    Bioorg Med Chem; 2009 Jun; 17(11):3756-62. PubMed ID: 19442526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral drugs for viruses other than human immunodeficiency virus.
    Razonable RR
    Mayo Clin Proc; 2011 Oct; 86(10):1009-26. PubMed ID: 21964179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amino Acid Ester Prodrugs of Nucleoside and Nucleotide Antivirals.
    Krecmerova M
    Mini Rev Med Chem; 2017; 17(10):818-833. PubMed ID: 28215138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical potential of the acyclic (and cyclic) nucleoside phosphonates: the magic of the phosphonate bond.
    De Clercq E
    Biochem Pharmacol; 2011 Jul; 82(2):99-109. PubMed ID: 21501598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?
    Andrei G; De Clercq E; Snoeck R
    Antiviral Res; 2004 Mar; 61(3):181-7. PubMed ID: 15168799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dancing with chemical formulae of antivirals: a personal account.
    De Clercq E
    Biochem Pharmacol; 2013 Sep; 86(6):711-25. PubMed ID: 23876344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infection due to acyclovir resistant herpes simplex virus in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Venard V; Dauendorffer JN; Carret AS; Corsaro D; Edert D; Bordigoni P; Le Faou A
    Pathol Biol (Paris); 2001 Sep; 49(7):553-8. PubMed ID: 11642018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections.
    De Clercq E
    Expert Rev Anti Infect Ther; 2003 Jun; 1(1):21-43. PubMed ID: 15482100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Murine cytomegalovirus resistant to antivirals has genetic correlates with human cytomegalovirus.
    Scott GM; Ng HL; Morton CJ; Parker MW; Rawlinson WD
    J Gen Virol; 2005 Aug; 86(Pt 8):2141-2151. PubMed ID: 16033961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options.
    Reusser P
    J Hosp Infect; 1996 Aug; 33(4):235-48. PubMed ID: 8864937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drugs--reports of new drugs recently approved by the FDA. Valacyclovir.
    Shinkai I; Ohta Y
    Bioorg Med Chem; 1996 Jan; 4(1):1-2. PubMed ID: 8689229
    [No Abstract]   [Full Text] [Related]  

  • 17. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro.
    Hartline CB; Gustin KM; Wan WB; Ciesla SL; Beadle JR; Hostetler KY; Kern ER
    J Infect Dis; 2005 Feb; 191(3):396-9. PubMed ID: 15633099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.
    De Clercq E
    Clin Microbiol Rev; 2003 Oct; 16(4):569-96. PubMed ID: 14557287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yet another ten stories on antiviral drug discovery (part D): paradigms, paradoxes, and paraductions.
    De Clercq E
    Med Res Rev; 2010 Jul; 30(4):667-707. PubMed ID: 19626594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into the mechanism of action of cidofovir and other acyclic nucleoside phosphonates against polyoma- and papillomaviruses and non-viral induced neoplasia.
    Andrei G; Topalis D; De Schutter T; Snoeck R
    Antiviral Res; 2015 Feb; 114():21-46. PubMed ID: 25446403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.